Vaginitis: Diagnosis and management

Postgraduate Medicine

Volumn 122, Issue 6, 2010, Pages 117-127

  Quan, Martin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bacterial vaginosis; Candida vaginitis; Imidazole; Metronidazole; Nitroimidazole; Tinidazole; Triazole; Trichomonas; Vaginitis

Indexed keywords

BORIC ACID; BUTOCONAZOLE; CLINDAMYCIN; CLOTRIMAZOLE; FLUCONAZOLE; FLUCYTOSINE; IMIDAZOLE; KETOCONAZOLE; METRONIDAZOLE; MICONAZOLE; NITROIMIDAZOLE; NYSTATIN; TERCONAZOLE; TINIDAZOLE; TIOCONAZOLE; TRIAZOLE; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT;

ARTICLE; ATROPHIC VAGINITIS; BEDTIME DOSAGE; CLINICAL COMPETENCE; CONTACT VAGINITIS; DESQUAMATIVE INFLAMMATORY VAGINITIS; DIFFERENTIAL DIAGNOSIS; DISULFIRAM LIKE REACTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FOREIGN BODY VAGINITIS; GASTROINTESTINAL SYMPTOM; GYNECOLOGIC DISEASE; HUMAN; IATROGENIC VAGINITIS; LABORATORY TEST; MEDICAL EXAMINATION; MEDICAL HISTORY; NAUSEA; NUCLEIC ACID ANALYSIS; PH; POINT OF CARE TESTING; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PRESCRIPTION; SEXUAL BEHAVIOR; SINGLE DRUG DOSE; TASTE DISORDER; TREATMENT DURATION; TRICHOMONIASIS; UNITED STATES; UNSPECIFIED SIDE EFFECT; UTERINE CERVICITIS; VAGINA CANDIDIASIS; VAGINA DISCHARGE; VAGINA PH; VAGINA SMEAR; VAGINAL POOL WET MOUNT; VAGINITIS; VOMITING; WHIFF TEST; WOMEN'S HEALTH; ADULT; FEMALE; HOSPITALIZATION; INTRAVAGINAL DRUG ADMINISTRATION; MICROBIOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PREGNANCY; PROGNOSIS; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; CALIFORNIA; CANDIDIASIS, VULVOVAGINAL; FEMALE; HUMANS; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROGNOSIS; RECURRENCE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TRICHOMONAS VAGINITIS; VAGINITIS; VAGINOSIS, BACTERIAL; YOUNG ADULT;

EID: 79952200810     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.11.2229     Document Type: Article

References (75)

1. Anderson MB, Klink K, Cohrssen A. Evaluation of vaginal complaints. JAMA. 2004;291(11):1368-1379.
2. Eckert LO. Clinical practice: acute vulvovaginitis. N Engl J Med. 2006;355(12):1244-1252.
3. Brown HL, Fuller DD, Jasper LT, Davis TE, Wright JD. Clinical evaluation of affirm VPIII in the detection and identification of Trichomonas vaginalis, Gardnerella vaginalis, and Candida species in vaginitis/vaginosis. Infect Dis Obstet Gynecol. 2004;12(1):17-21.
4. Landers DV, Wiesenfeld HC, Heine RP, Krohn MA, Hillier SL. Predictive value of the clinical diagnosis of lower genital tract infection in women. Am J Obstet Gynecol. 2004;190(4):1004-1010.
5. Ferris DG, Nyirjesy P, Sobel JD, Soper D, Pavletic A, Litaker MS. Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol. 2002;99(3):419-425.
6. Allen-Davis JT, Beck A, Parker R, Ellis JL, Polley D. Assessment of vulvovaginal complaints: accuracy of telephone triage and in-office diagnosis. Obstet Gynecol. 2002;99(1):18-22.
7. Cibley LJ, Cibley LJ. Cytolytic vaginosis. Am J Obstet Gynecol. 1991;165(4 pt 2):1245-1249.
8. Ledger WJ, Monif GR. A growing concern: inability to diagnose vulvovaginal infections correctly. Obstet Gynecol. 2004:103(4):782-784.
9. Fleury FJ. Adult vaginitis. Clin Obstet Gynecol. 1981:24(2):407-438.
10. Nyirjesy P, Peyton C, Weitz MV, Mathew L, Culhane JF. Causes of chronic vaginitis. Obstet Gynecol. 2006;108(5):1185-1191.
11. Quan M. Diagnosis and management of infectious vaginitis. J Am Board Fam Pract. 1990:3(3):195-205.
12. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med. 2005;353(18):1899-1911.
13. Swidsinski A, Mendling W, Loening-Baucke V, et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol. 2008;198(1):97. e1-e6.
14. Menard JP, Mazouni C, Salem-Cherif I, et al. High vaginal concentrations of Atopobium vaginae and Gardnerella vaginalis in women undergoing preterm labor. Obstet Gynecol. 2010;115(1):134-140.
15. Sobel JD. What's new in bacterial vaginosis and trichomoniasis. Infect Dis Clin North Am. 2005;19(2):387-406.
16. Brand JM, Galask P. Trimethylamine: the substance mainly responsible for the fishy odor often associated with bacterial vaginosis. Obstet Gynecol. 1986;68(5):682-685.
17. Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Trans Dis. 2007;34(11):864-869.
18. Fethers KA, Fairley CK, Hocking JS, Gurrin LC, Bradshaw CS. Sexual risk factors and bacterial vaginosis: a systematic review and meta-analysis. Clin Infect Dis. 2008;47(11):1426-1435.
19. Klebanoff MA, Schwebke JR, Zhang J, et al. Vulvovaginal symptoms in women with bacterial vaginosis. Obstet Gynecol. 2004;104(2):267-272.
20. Leitich H, Kiss H. Asymptomatic bacterial vaginosis and intermediate flora as risk factors for adverse pregnancy outcomes. Clin Obstet Gynecol. 2007;21(3):375-390.
21. Nygren P, Fu R, Freeman M, Bougatsos C, Klebanoff M, Guise JM; U.S. Preventive Services Task Force. Evidence on the benefits and harms of screening and treating pregnant women who are asymptomatic for bacterial vaginosis: an update review for the U.S. preventive services task force. Ann Intern Med. 2008;148(3):220-233.
22. Koumans EH, Markowitz LE, Hogan V; CDC BV Working Group. Indications for therapy and treatment recommendations for bacterial vaginosis in nonpregnant and pregnant women: a synthesis of data. Clin Infect Dis. 2002;35(suppl 2):S152-S172.
23. Nyirjesy P. Vulvovaginal candidiasis and bacterial vaginosis. Infect Dis Clin N Am. 2008;22(4):637-652.
24. Atashili J, Poole C, Ndumbe PM, Adimora AA, Smith JS. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS. 2008;22(12):1493-1501.
25. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol. 2005;43(5):2155-2162.
26. Sobel JD. Vulvovaginal candidosis. Lancet. 2007;369(9577):1961-1971.
27. Centers for Disease Control and Prevention; Workowski KA, Berman SM. Sexually transmitted disease treatment guidelines 2006. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2006:55(RR-11):1-94.
28. Whittington MJ. Epidemiology of infections with Trichomonas vaginalis in the light of improved diagnostic methods. Br J Vener Dis. 1957:33(2):80-91.
29. ACOG Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists, Number 72, May 2006: Vaginitis. Obstet Gynecol. 2006;107(5):1195-1206.
30. Wendel KA, Workowski KA. Trichomoniasis: challenges to appropriate management. Clin Infect Dis. 2007;44(suppl 3):S123-S129.
31. Peterman TA, Tian LH, Metcalf CA, et al: Persistent, undetected Trichomonas vaginalis infections? Clin Infect Dis. 2009:48(2):259-260.
32. Soper D. Trichomoniasis: under control or undercontrolled. Am J Obstet Gynecol. 2004:190(1):281-290.
33. Spence DS, Melville C. Vaginal discharge. BMJ. 2007;335(7630):1147-1151.
34. French L, Horton J, Matousek M. Abnormal vaginal discharge: using office diagnostic testing more effectively. J Fam Pract. 2004;53(11):805-814.
35. Miller WC, Zenilman JM. Epidemiology of chlamydial infection gonorrhea, and trichomoniasis in the United States-2005. Infect Dis Clin North Am. 2005;19(2):281-296.
36. Marrazzo JM, Martin DH. Management of women with cervicitis. Clin Infect Dis. 2007;44(suppl 3):S102-S110.
37. Marrazzo JM, Handsfield HH, Whittington WL. Predicting chlamydial and gonococcal cervical infection: implications for management of cervicitis. Obstet Gynecol. 2002:100(3):579-584.
38. Sharp HC. Vulvovaginal conditions mimicking vaginitis. Clin Obstet Gynecol. 1993;36(1):129-136.
39. Bachman GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician. 2000;61(10):3090-3096.
40. North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy: 2007 position statement of the North American Menopause Society. Menopause. 2007;14(3 pt 1):355-370.
41. Murphy R, Edwards L. Desquamative inflammatory vaginitis: what is it? J Reprod Med. 2008:53(2):124-128.
42. Sobel JD. Desquamative inflammatory vaginitis: a new subgroup of purulent vaginitis responsive to topical 2% clindamycin therapy. Am J Obstet Gynecol. 1994;171(5):1215-1220.
43. Horowitz BJ, Mardh P, Nagy E, Rank EL. Vaginal lactobacillosis. Am J Obstet Gynecol. 1994;170(3):857-861.
44. Donders GG, Vereecken A, Bosmans E, Dekeersmaecker A, Salembier G, Spitz B. Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis. BJOG. 2002;109(1):32-43.
45. Joesoef MR, Karundeng A, Runtupalit C, Moran JS, Lewis JS, Ryan CA. High rate of bacterial vaginosis in women with intrauterine devices in Manado, Indonesia. Contraception. 2001;64(3):169-172.
46. Meirik O. Intrauterine devices-upper and lower genital tract infections. Contraception. 2007;75(6suppl):S41-S47.
47. Geisler WM, Venglarik M, Schwebke JR. Vaginal leucocyte counts in women with bacterial vaginosis: relation to vaginal and cervical infections. Sex Trans Infect. 2004;80(5):401-405.
48. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74(1):14-22.
49. Sobel JD, Vazquez J, Lynch M, et al. Vaginitis due to Saccharomyces cerevisiae: epidemiology, clinical aspects, and therapy. Clin Infect Dis. 1993;16(1):93-99.
50. Thinkhamrop J, Lumbiganon P, Thongkrajel P, Chongsomchai C, Pakarasang M. Vaginal fluid pH as a screening test for vaginitis. Int J Gynecol Obstet. 1999;66(2):143-148.
51. West B, Morison L, Van der Loeff MS, et al. Evaluation of a new rapid diagnostic kit (FemExam) for bacterial vaginosis in patients with vaginal discharge syndrome in the Gambia. STD. 2003;30(6):483-489.
52. Lowe NK, Neal JL, Ryan-Wenger NA. Accuracy of the clinical diagnosis of vaginitis compared with a DNA probe laboratory standard. Obstet Gynecol. 2009;113(1):89-95.
53. Huppert JS, Batteiger BE, Braslins P, et al. Use of an immunochromatographic assay for rapid detection of trichomonas vaginalis in vaginal specimens. J Clin Microbiol. 2005;43(2):684-687.
54. Sobel JD, Kapernick PS, Zervos M, et al: Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol. 2001;185(2):363-369.
55. Sobel JD, Chaim W, Nagappan V, et al. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. Am J Obstet Gynecol. 2003;189(5):1297-1300.
56. Horowitz BJ. Topical flucytosine therapy for chronic recurrent Candida tropicalis infections. J Reprod Med. 1986;31(9):821-824.
57. Sobel JD. Recurrent vulvovaginal candidiasis. N Engl J Med. 1986;315(23):1455-1458.
58. Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med. 2004;351(9):876-883.
59. Fung HB, Doan T. Tinidazole: a nitroimidazole antiprotozoal drug. Clin Ther. 2005;27(12):1859-1884.
60. Okun N, Gronau KA, Hannah ME. Antibiotics for bacterial vaginosis or trichomonas vaginalis in pregnancy: a systematic review. Obstet Gynecol. 2005:105(4):857-868.
61. Nyirjesy P, Sobel JD, Weitz MV, Leaman DJ, Gelone SP. Difficult-to-treat trichomoniasis: results with paromomycin cream. Clin Infect Dis. 1998;26(4):986-988.
62. Poppe WA. Nitroimidazole-resistant vaginal trichomoniasis treated with paromomycin. Eur J Obstet Gynecol Reprod Biol. 2001;96(1):119-120.
63. Tayal SC, Ochogwu SA, Bunce H. Paromomycin treatment of recalcitrant Trichomonas vaginalis. Int J STD AIDS. 2010;21(3):217-218.
64. Gutman RE, Peipert JF, Weitzen S, Blume J. Evaluation of clinical methods for diagnosing bacterial vaginosis. Obstet Gynecol. 2005;105(3):551-556.
65. Nugent RP, Krohn MA, Hillier S. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991:29(2):297-301.
66. Pheifer TA, Forsyth PS, Durfee MA, Pollock HM, Holmes KK. Nonspecific vaginitis: role of Haemophilus vaginalis and treatment with metronidazole. N Engl J Med. 1978;298(26):1429-1434.
67. Livengood CH, Ferris DG, Wiesenfeld HC, et al. Effectiveness of two tinidazole regimens in treatment of bacterial vaginosis: a randomized controlled trial. Obstet Gynecol. 2007:110(2 pt 1):302-309.
68. Bunge KE, Beigi RH, Meyn LA, Hillier SL. The efficacy of retreatment with the same medication for early treatment failure of bacterial vaginosis. Sex Trans Dis. 2009;36(11):711-713.
69. Sobel JD, Ferris D, Schwebke J, et al. Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis. Am J Obstet Gynecol. 2006;194:1283-1289.
70. Reichman O, Akins R, Sobel JD. Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis. Sex Trans Dis. 2009;36(11):732-734.
71. Schwebke JR, Desmond R. A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases. Am J Obstet Gynecol. 2007;196(6):517. e1-e6.
72. Ness RB, Kip KE, Soper DE. Variability of bacterial vaginosis over 6-to 12-month intervals. Sex Trans Dis. 2006;33(6):381-385.
73. Klebanoff MA, Hauth JC, MacPherson CA, et al; National Institute for Child Health and Development Maternal Fetal Medicine Units Network. Time course of the regression of asymptomatic bacterial vaginosis in pregnancy with and without treatment. Am J Obstet Gynecol. 2004;190(2):363-370.
74. Carey JC, Klebanoff MA, Hauth JC, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. N Engl J Med. 2000:342(8):534-540.
75. U.S. Preventive Services Task Force. Screening for bacterial vaginosis in pregnancy to prevent preterm delivery: U.S. preventive services task force recommendation statement. Ann Intern Med. 2008:148(12):214-219.